The NDC directory covers drugs that are already approved and marketed. This section tracks what is still in testing — by therapeutic area, phase and how the treatment is given.
Large comparative studies, typically 1–3 years from an FDA decision. This is where tomorrow's NDC codes come from.
Mid-size studies testing whether the treatment actually works for the condition, usually 3–5 years out.
First-in-human safety and dosing work. Long-term, but every approved drug started here.
Each area maps to the same pharmacologic classes used in the NDC directory, so you can move between an approved drug and what is coming next.
Semaglutide, Tirzepatide, Liraglutide — diabetes & weight management therapies
Atorvastatin, Rosuvastatin, Simvastatin — lipid-lowering & cholesterol control
Empagliflozin, Dapagliflozin — glycaemic control, heart failure & chronic kidney disease
Pembrolizumab, Nivolumab, Adalimumab — targeted oncology & autoimmune biologics
Metoprolol, Atenolol, Propranolol — hypertension, angina & arrhythmia management
Ibuprofen, Naproxen, Celecoxib — pain relief, anti-inflammatory & antipyretic
Amphetamine/Dextroamphetamine, Methylphenidate — ADHD & narcolepsy
Sertraline, Escitalopram, Fluoxetine — major depression & anxiety disorders
Once a treatment is marketed it gets a National Drug Code, a J-Code and a CPT administration code — all searchable in the directory.